* arginine * nifedipine * valsartan rats, as well as in the human forearm and coronary circulation of hypertensive patients. [19] [20] [21] In the aorta of hypertensive rats, antihypertensive treatment with reserpine, hydrochlorthiazide, and hydralazine improves endothelial function, indicating that endothelial dysfunction in hypertension is reversible, at least in the aorta. 22 In recent years, several new classes of antihypertensive drugs such as angiotensin-converting enzyme inhibitors and calcium antagonists have been developed, [23] [24] [25] [26] and more recently, orally active, nonpeptide angiotensin II receptor antagonists (ie, losartan27 and valsartan28). Angiotensin II receptor antagonists have antihypertensive properties and may represent more effective inhioitors of the renin-angiotensin system than angiotensinconverting enzyme inhibitors. 29 The present study was designed to investigate the effects of chronic antihypertensive therapy with the novel, nonpeptide angiotensin II (AT1) receptor antagonists CGP 48369 and valsartan compared with those of a converting enzyme inhibitor or calcium antagonist on the endothelial L-arginine pathway and vascular smooth muscle function in the coronary circulation of normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats. 
Experimental Setup
Left anterior descending coronary arteries were dissected free under a microscope (Wild-Leitz). Rings (1.8 to 2 mm in length; internal diameter, 300 jam) were mounted in a modified version of the myograph system described by Mulvany and Halpern30 for measurement of isometric force. Organ chambers were filled with 12.5 mL of control solution (37°C, 95% 02/5% C02). Rings were held in place by means of two stiff tungsten wires (diameters, 30 and 50 ,um) that were carefully passed through the lumen and fastened to clamps attached to a force transducer (Showa Sokki LB-5, Rikadenki) and to a micromanipulator (Narishige) for adjustment of muscle length. The isometric force-to-length relation to each ring was determined by repeated exposures to 100 mmol/L KCl at increasing levels of vessel length. The vessels were then held at the optimal point of the length-to-tension relation at which maximum active force was produced for all subsequent experiments (200±8 mg).
Protocols
The relaxing effects of acetylcholine and 3-morpholinosydnonimine (SIN-1) were studied by adding increasing concentrations of the drugs (10`to 10 To study contractions evoked by serotonin (10-`to 10m ol/L), increasing concentrations of the monoamine were added in a cumulative fashion to quiescent preparations and compared with the contraction induced by KCl (100 mmol/L).
Drugs
The following drugs were used (all from Sigma Chemical Co unless otherwise stated): acetylcholine hydrochloride, bradykinin, indomethacin, L-NAME, L-NMMA, methylene blue, pentobarbital (Abbott), 5-hydroxytryptamine creatinine sulfate (serotonin; Serva), SIN-1 (Hoechst Pharmaceutica31), substance P, and thrombin. All concentrations of the drugs used in vitro are expressed as final molar concentration in the organ chambers. Benazepril HCl,24 benazeprilat (active form), CGP 48369,32 valsartan,28 and nifedipine were synthesized at the Chemistry Department, CIBA-GEIGY, Basel, Switzerland.
Calculations and Statistical Analysis
For statistical analysis, the concentration causing half-maximal contraction (EC50) or half-maximal inhibition of a preceding contraction (ICo), the maximal relaxation (percent), and the area under the concentration-response curve ( Other agonists of the L-arginine pathway such as bradykinin (10-6 mol/L, n=3), substance P (10-6 mol/L, n=3), or thrombin (1 U/mL, n=3) were ineffective in this preparation (Fig 2) . Relaxations Table 3 ).
Relaxations to SIN-I
The relaxations to the nitric oxide donor SIN-1 (10-t o 10-5 mol/L) were identical in untreated and treated SHR (n=4 , Fig 3, right) and WKY. The IC5 values, the maximal responses, and the areas under the concentration-response curve of the relaxations to SIN-i in SHR and WKY are listed in Table 3 .
Contctions to Serotonin
In SHR and WKY, the contractions induced by serotonin (10-`to 10 *Negative log lCw (half-maximal inhibition of a preceding contraction induced with serotonin 10-6 mol/L). tPreceding contraction induced by serotonin 10 6 mol/L was taken as 100%.
*Area under the concentration-response curve expressed in arbitrary units (1 to 1000) .
§P<.05 vs untreated SHR. that has not yet been compared with angiotensin-converting enzyme inhibitors or calcium antagonists. Under the conditions of this study, all drugs used, ie, the nonpeptide angiotensin receptor antagonists valsartan and CGP 48369, benazepril HCl, and nifedipine, all markedly increased both the sensitivity and maximal response to the endothelium-dependent vasodilator acetylcholine. Since the response to the nitric oxide donor SIN-131,36 and contractions to serotonin were unaltered, this indicates that endothelial function, ie, the production of nitric oxide, was similarly improved by all antihypertensive regimens, whereas vascular smooth muscle function remained unaltered. Since in the SHR, all drugs similarly reduced the rise in arterial blood pressure and led to an identical improvement of endothelial function, blood pressure lowering by itself must be the most important determinant. In line with that interpretation, in WKY, chronic nifedipine therapy did not affect blood pressure or endothelium-dependent relaxations to acetylcholine. These results confirm the above-mentioned hypothesis that in the SHR, high blood pressure does indeed reduce coronary endothelial function.
Coronary artery disease is an important vascular complication of hypertension. 47 In most clinical studies, antihypertensive therapy did not affect coronary morbidity and mortality.48-50 A meta-analysis, however, indicates that antihypertensive therapy does reduce coronary artery disease in hypertensive subjects, although less so than cerebrovascular events. 51 The results of this experimental study suggest that antihypertensive drugs that interfere with the renin-angiotensin system or calcium influx improve coronary endothelial function, largely because of their blood pressure-lowering effects, provided that therapy is started early. The improvement in endothelial function may be important, because endothelial cells play a protective role in the coronary circulation as inhibitors of platelet function (through the release of nitric oxide and prostacyclin36,52) as well as by preventing coronary vasospasm (mainly through the release of nitric oxide in response to platelet-derived products and other vasoconstrictor substances53).
